Ahead Together
0:31
Investors
We have announced our third quarter 2022 results.
Press releases
- New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
- Statement: Zantac (ranitidine) litigation
- Jemperli (dostarlimab-gxly) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSKUS on twitter
GSK Global links
Visit our Global site for additional features